Let's look at some numbers. Currently we have roughly 150 million shares outstanding, and 500 million share authorized. What would happen if the company said they'll need to get substantial additional funding, but will put off any discussions of a reverse split for at least a year in the belief that a year from now they'll have a few fully approved patents, and at least two products in Phase 2 clinical trials that are fully covered by patents.
To begin with, I believe our price would almost immediately reach $.10 to $.25, if they determined they needed $50 million, worst case they'd approach their authorized share limit, but if they waited for patent approvals, they could do far better than that.
By next year, with a few patent approvals and drugs in Phase 2 trials with efficacy demonstrated, I believe a market cap between $.5 and $1 billion is very possible, even with full dilution our share price would be somewhere in the $1 to $2 range. At that point a 1 for 2 or 3 reverse split would bring the price to striking distance of the Nasdaq, if not over the top, and would bring the share count to the point that substantial room of growth again existed.
Of course if the good news was better, fewer share would be needed for funding, and the numbers would only get better. Of course the opposite is true as well, if no patents are approved, or efficacy isn't seen in our drugs in trials, we could be bankrupt. The reality is, that worst case scenario is true whether a R/S is done or not, success requires gaining the intellectual property rights and proving they work. I simply don't believe that with 150 million shares currently outstanding it requires taking that number down to 1.5 million shares or less. If they were speaking about bringing the shares down to 50 million, it could be a figure worth considering, but I'd still suggest they gain share price by getting things done first.
Gary
